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A hallmark of cardiovascular disease (hypertension, myocardial in-
farction, heart failure and malignant ventricular arrhythmia) is cardiac
autonomic dysregulation (Floras, 2003). The phenotype of impaired
parasympathetic responsiveness and sympathetic hyperactivity in ex-
perimental animal models (Ma et al., 1997; Ishise et al., 1998; Sun et
al., 1999; Motte et al., 2005) is also well documented in large scalethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and is predictive of morbidity and mortality (La Rovere et al., 1998;
Nolan et al., 1998). Despite advances in emergency revascularisation
strategies for myocardial infarction, device therapy for heart failure
and secondary prevention pharmacotherapies, mortality from malig-
nant ventricular arrhythmia remains high. Patients at highest risk or
those with haemodynamically signiﬁcant ventricular arrhythmia can
be treated with implantable cardioverter deﬁbrillators (ICD) (AVID,
1997;Moss et al., 2002; Bardy et al., 2005), but themorbidity and reduc-
tion in quality of life due to the burden of ventricular arrhythmia and
shock therapy persists. Therefore, future therapies must aim to target
the underlying pathophysiology that contributes to the generation of
ventricular arrhythmia. Emerging evidence now suggests that modula-
tion of the autonomic nervous system with neuro-axis targeting is
gaining utility as a novel therapy in this patient group (Ardell et al.,
2016; Shivkumar et al., 2016).2. The integrated heart-brain neuro-axis
The autonomic nervous system functions to tightly regulate cardiac
excitability and contractile function (Habecker et al., 2016). The inter-
connected architecture has been elegantly explored and described by
Ardell and Armour (Armour, 2008) based upon physiological data
from multiple studies across varying spatial domains. This system is
considered as a manifestation of three levels of neural hierarchy, mov-
ing away from the historical reciprocal thesis of cardiac control where
the two armsof theANS acted as ‘accelerator and brake’ on cardiac func-
tion. Instead, the excitability of cardiac parasympathetic pathways or
sympathetic pathways depends on tonic inputs to synaptic junctions
at several stages in the brain, spinal cord and in the extrinsic and intrin-
sic cardiac ganglia (Gebber et al., 1996; Kember et al., 2011; Fukuda et
al., 2015). Level 1 encompasses the spinal cord andmedulla with higher
centremodulation (McAllen et al., 2011; Harper et al., 2013). Level 2 in-
corporates extracardiac neurons such as the stellate ganglia (Armour,
1986a, 1986b; Ardell et al., 2009) and level 3 includes all the intrinsic
cardiac ganglia and nerves (Armour, 2008). Cardiac afferents and
extracardiac circulatory receptors serve to transmit beat to beat sensory
information to levels 1 and 2 and processing at these levels allows feed-
back loops which maintain physiological electrical and contractile sta-
bility in normal and stressed states (Ardell et al., 2016).
In the setting of cardiovascular disease or cardiac injury such as
myocardial infarction, neurophysiological changes take place at distinct
levels in the neural circuitry (Rubart and Zipes, 2005; Vaseghi and
Shivkumar, 2008). Effects at the level of the organ such as scar formation
and ﬁbrosis contribute to heterogeneities in electrical activation and
may contribute to the creation of ﬁxed and functional substrate for re-
entrant arrhythmia (Stevenson, 2009). There is also afferent mediated
activation of neurohumoural systems and increased sympathetic stimu-
lation and reduced vagal tone (Wang et al., 2014). In the short term, this
is an adaptive response to maintain cardiac output (Kember et al.,
2013), although at the cost of increased myocardial oxygen demand.
However, following the acute injury phase, there is continued abnormal
cardiac afferent signalling resulting in a maladaptive environment of
persistent sympathetic activity (Zucker et al., 2012) that contributes to
remodelling and the progression of cardiac disease that can ultimately
lead to fatal arrhythmia.
Understanding of this complex cardiac neural-axis has led to
targeted autonomic modulation therapies for heart failure and arrhyth-
mia aimed at the cervical cardiac vagus and sympathetic nervous sys-
tem respectively (Ardell et al., 2016). This review explores recent
advances inmechanistic research in both limbs of the ANS and potential
avenues for translation into clinical therapy. In addition, we also discuss
the relationship of these ﬁndings in the context of the reported efﬁcacy
of current neuromodulatory strategies in the management of ventricu-
lar arrhythmia.3. Mechanisms of ventricular arrhythmia
An understanding of the mechanisms responsible for the initiation
and maintenance of ventricular arrhythmia is critical if effective treat-
ment strategies are to be investigated and developed. The principle con-
tributing factor to the onset of arrhythmia is re-entry. Fibrillation occurs
when an electrical wave-break induces re-entry and leads to a sequence
of new wave-breaks (Garﬁnkel et al., 2000; Weiss et al., 2000, 2011).
Wave-break is affected by static and dynamic factors and these inﬂu-
ence the likelihood of local wave-break resulting in re-entry. Static fac-
tors are predominantly anatomical such as scar and ﬁbrosis and lead to
tissue heterogeneity and electrical remodelling that is ﬁxed. Key com-
ponents of dynamic factors are changes inmembrane voltage and intra-
cellular calcium,which are inﬂuenced by the autonomic nervous system
and act synergistically with static factors to destabilise electrical activa-
tion (Weiss et al., 2000).
4. The effects of sympathetic stimulation on cardiac electrophysiology
Contemporary research has led to a spectrum of neuro-axial thera-
pies in the setting of patients at high risk of malignant ventricular ar-
rhythmia. This has been based on mechanistic evidence from models
of sympathetic hyperactivity at the level of the organ in animals
(Habecker et al., 2016), and more recently from human studies
(Shivkumar et al., 2016).
The effect of sympathetic stimulation on global ventricular electro-
physiology has been studied extensively in animal models
(Mantravadi et al., 2007; Ng et al., 2009) and humans (Vaseghi et al.,
2014). In the rabbit heart in-vitro, sympathetic stimulation using an
electrode inserted in the spinal canal produces regional apex-base
changes in restitution kinetics (Mantravadi et al., 2007; Ng et al.,
2009). This is presumablymediated by regional differences sympathetic
innervation and IKs distribution, potentially inﬂuencing the vulnerabili-
ty to arrhythmia. The ability of local changes in sympathetic activity to
trigger ventricular arrhythmias is well established (Nash et al., 2001).
Epicardial injection of NE in the pig elicits triggered automaticity, and
computational modelling implicated a Ca2+ overload mechanism,
supporting the hypothesis that heterogeneity or gradients of activation
are pro-arrhythmic. The functional effect of post myocardial infarction
remodelling has been elegantly demonstrated in patients undergoing
endocardial and epicardialmapping as part of therapeutic catheter abla-
tion procedures (Vaseghi et al., 2012). The effect of direct adrenergic
stimulation with isoproterenol or reﬂex sympathetic stimulation in re-
sponse to baroreﬂex activation elicites regional changes in
repolarisation dynamics. This includes abnormal neural control in re-
mote areas where a lack of action potential duration (APD) shortening
in response to baroreﬂex activation suggests functional denervation.
These results were reproduced in a porcinemodel of myocardial infarc-
tion following direct stellate ganglia stimulation (Ajijola et al., 2013). In-
terestingly, histological and molecular analysis of stellate ganglia tissue
from these animals also demonstrates remodellingwith increased tyro-
sine hydroxylase staining (Rajendran et al., 2016). This has been repli-
cated in studies on stellate ganglia tissue from patients undergoing
sympathectomy for refractory ventricular arrhythmia (Ajijola et al.,
2012b).
5. Efferent cardiac sympathetic neurotransmission in health and
disease
A growing body of work has demonstrated that sympathetic hyper-
activity associated with several cardiovascular diseases resides, at least
in part, with dysregulation in post-ganglionic cardiac sympathetic neu-
rons. This is of particular interest as this area is perhaps more easily ac-
cessible for therapeutic intervention compared to the brainstem.
Emerging evidence suggests that impaired NO and intracellular calcium
handling are key intermediaries in sympathetic dyautonomia, since
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type itself. For example, hypertension is associated with neurohumoral
activation (Ely et al., 1997; Yemane et al., 2010) resulting in decreased
parasympathetic responsiveness (Langewitz et al., 1994), sympathetic
hyperactivity (Burns et al., 2007; Malpas, 2010; Grassi et al., 2015)
and increased norepinephrine (NE) release (Rumantir et al., 2000).
Post-ganglionic sympathetic neurons from the stellate ganglia of spon-
taneously hypertensive rats (SHRs) have a greater depolarisation-
evoked intracellular Ca2+ transient compared to normotensive controls.
The Ca2+ proﬁle was observed in cells fromneonatal, young pre-hyper-
tensive and adult hypertensive animals suggesting the molecular phe-
notype is well conserved (Li et al., 2012). Moreover, the neuronal
Ca2+ current is increased in neurons from the SHR indicating that dys-
regulation of ion channel physiology contributes to the alteration in
Ca2+ transients (Lu et al., 2015). In addition, neuronal NE uptake by
the NE uptake transporter (NET) is also decreased in stellate neurons
from the SHR (Shanks et al., 2013a), thereby contributing to the in-
creased NE spill over and heightened sympathetic responsiveness in
both the adult (Herring et al., 2011) and young SHR before they develop
high blood pressure (Shanks et al., 2013b). Of interest, the sympathetic
phenotype can be rescuedwith site-speciﬁc nNOS gene transfer in tyro-
sine hydroxylase positive neurons (Wang et al., 2006) resulting in a re-
duction in Ca2+ transients and inhibition of neurotransmission.
5.1. How does nNOS confer its protective effects?
Cytosolic nNOS translocates to caveolae post myocardial infarction
and this is facilitated by its own shuttle adaptor protein, NOS1-AP/
CAPON (Beigi et al., 2009). NOS1AP provides an interesting potential
mechanistic link between cellular physiology and arrhythmia as
GWAS studies have linked single nucleotide polymorphisms (SNPs) in
the gene for NOS1-APwithQTvariation (Arking et al., 2006) and sudden
cardiac death (Westaway et al., 2011) in the general population. These
SNPs are also risk factors for sudden cardiac death in patients with
inherited long QT syndrome (Crotti et al., 2009; Tomas et al., 2010).
NOS1AP is highly expressed in sympathetic neurons from the stellate
neurons and is down regulated in the SHR (Lu et al., 2015). Overexpres-
sion of NOS1-AP in the SHR increases nNOS activity without a change in
nNOS expression itself resulting in a reduction in neuronal Ca2+ tran-
sients and NE release (Lu et al., 2015). These effects are abolished by
nNOS inhibition, indicating a functional role for NOS1-AP in the NOme-
diated modulation of neurotransmission and therefore may represent a
novel therapeutic target for modulating the gain of sympathetic activity
in high risk populations (Li and Paterson, 2016).
5.2. Interaction with neurotrophic factors
It is interesting that sympathetic neuronal hyperactivity begins prior
to the development of the disease phenotype and continues as the dis-
ease progresses. Sympathetic nerves project into themyocardium along
with the parasympathetic innervation and together with sensory ﬁbres
act to tightly regulate cardiac function (Fukuda et al., 2015). The density
of innervation corresponds to physiological triggers such as
neurotrophins, of which nerve growth factor (NGF) is a prototypic
member. NGF is upregulated in cardiac hypertrophy (Kimura et al.,
2007) and also after myocardial infarction in a canine model (Zhou et
al., 2004), leading to heterogeneous hyperinnervation. The relevance
of this to arrhythmia was demonstrated by NGF infusion after myocar-
dial infarction which resulted in an increased incidence of ventricular
arrhythmia and sudden cardiac death (Cao et al., 2000). However, NGF
also plays a role in the development of sensory innervation, and affer-
ents responsible for the transduction of stimuli such as hypoxia, acidosis
and pain duringmyocardial ischaemia (Hua et al., 2004). Sensory inner-
vation has been shown to be impaired in conditions such as diabetes
mellitus andmay contribute to the phenomenon of silentmyocardial is-
chaemia and the genesis of malignant ventricular arrhythmia (Faermanet al., 1977). Direct gene transfer of NGF into diabetic rat hearts im-
proved cardiac sensory innervation (Ieda et al., 2006) and recombinant
NGF has been shown to be safe when administered to diabetic patients
with polyneuropathy (Apfel et al., 2000). Pathways such as this require
further study to determine the contrasting effects on sensory innerva-
tion and potential deleterious effects of heterogeneous hyper-innerva-
tion seen post myocardial infarction. An alternative approach is to
target the chondroitin sulfate proteoglycans present in scar tissue fol-
lowing MI which prevents sympathetic reinnervation by binding the
neuronal protein tyrosine phosphatase receptor σ (PTPσ). Targeting
PTPσ either genetically or pharmacologically restores sympathetic in-
nervation to the scar and markedly reduces arrhythmia susceptibility
in the immediate post-MI period (Gardner et al., 2015).
There are also chronic temporal changes in innervation that take
place during disease progression in heart failure. Chronic sympathetic
hyperactivity and exposure to NE leads to a reduction in NGF, and in se-
vere decompensated heart failure, loss of innervation is seen (anatomic
denervation). Heart failure is also associated with changes in other in-
ﬂammatory and neurohumoural pathways including a range of growth
factors and cytokines. Candidate molecules include leukemia inhibitory
factor (LIF) and members of the interleukin (IL-6) family (Habecker et
al., 2016). These molecules can induce changes in stellate ganglia neu-
rons with increased expression of cholinergic markers via a gp130 sig-
nalling pathway (Kanazawa et al., 2010). This trans-differentiation
process is of unknown signiﬁcance, but there are data from murine
studies of hypoxia induced heart failure in which sympathetic nerve
speciﬁc gp130 knockout had adverse outcomes compared to controls
indicating a potential protective role. A recent study also demonstrates
neural remodelling including increased nNOS expression in a porcine
model of chronicmyocardial infarctionmodel particularly in the ventral
interventricular ganglionated plexi, dorsal root ganglia and stellate gan-
glia (Nakamura et al., 2016). The spatio-temporal features of changes in
cardiac innervation continue to be the subject of study andmay yield an
alternative therapeutic approach in modifying the risk of ventricular
arrhythmia.
6. The anti-arrhythmic effect of the vagus: historical perspective and
emerging mechanistic insights
Efferent vagal innervation of the heart is classically thought to be
only concentrated in the sinoatrial, atrial and atrioventricular nodal re-
gions. Advances in anatomical techniques have however challenged the
historical perspective that this innervation is restricted to the atria and
structures in the conduction system (Randall, 1984; Levy and Martin,
1996). Immunohistochemical techniques identifying either acetylcho-
linesterase (AChE) and more recently choline acetyltransferase (ChAT)
have led to revisions in this dogma,where signiﬁcant cholinergic epicar-
dial and endocardial innervation of atria and ventricles across a range of
mammalian species has been observed (Blomquist et al., 1987; Pauza et
al., 2002; Batulevicius et al., 2005; Ulphani et al., 2010). There is howev-
er considerable species variation in sites of preganglionic nerve termi-
nations in parasympathetic ganglia (Pardini et al., 1987; Singh et al.,
1996; Coote, 2013) and this may underlie some of the species depen-
dent variation in response to VNS reported in the literature. Despite a
sparse innervation of the ventricle in a variety of species, functionally
VNS can produce a decrease in left ventricular contractility in human
subjects (Lewis et al., 2001).
The anti-ﬁbrillatory effect of the vagus was ﬁrst described in 1859
(Einbrodt, 1859) and elegant studies have demonstrated that VNS de-
creases the occurrence of ventricular arrhythmia during CAO, ischae-
mia-reperfusion and also in the absence of structural heart disease
(Kent et al., 1973; Corr and Gillis, 1974; Myers et al., 1974; Kolman et
al., 1975; Yoon et al., 1977). The most compelling demonstration of
the anti-ﬁbrillatory effect of VNS and the importance of vagal tone has
come from Peter Schwartz and colleagues. They employed a canine
model of healed anterior myocardial infarction at increased risk of
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workload on a treadmill post-infarction with concurrent occlusion of
the circumﬂex artery resulting in VF in 60% of animals (Schwartz et
al., 1984, 1988). Animals that survived this stressor had increased
vagal tone indicated by a reduction in heart rate during exercise, and
this protective effect was abolished by muscarinic blockade with atro-
pine. Direct VNS in the samemodel system also resulted in a signiﬁcant
reduction in VF occurrence (Vanoli et al., 1991).
The mechanistic basis of this anti-ﬁbrillatory property of VNS can be
considered in terms of the effect on static and dynamic contributors to
the development of ventricular arrhythmias. Tissue heterogeneity due
to scar and ﬁbrosis after myocardial infarction is a key substrate for
the initiation and maintenance of re-entry and ventricular tachycardia
(Stevenson, 2009). Uniform activation of the ventricle is dependent
upon gap junction distribution and function. Alteration in gap junction
expression is seen in the context of ischaemia, HF and cardiomyopathy
and these groups are at high risk of ventricular arrhythmia. Ando et al.
(Ando et al., 2005) demonstrated that VNS resulted in maintenance of
gap junction function as evidenced by preservation of phosphorylated
connexin 43 and an 87% reduction in postmyocardial infarction ventric-
ular tachycardia (VT) in rats. Similar results have been reported by
Sabbah (Sabbah, 2011) where chronic VNS resulted in normalisation
of connexin 43 expression in a canine model of micro-embolisation in-
duced HF. These pre-clinical observations of positive remodelling of
substrate by VNS are exciting observations and clinical studies with
VNS in HF patientsmay be able to assess this effect via complex imaging
studies. Inﬂammatory pathways play a key role in ﬁbrosis (Nicoletti and
Michel, 1999), scar formation and hypertrophy (Klein et al., 2000). VNS
in the canine HFmodel normalises levels of IL-6 and TNFα (Wang et al.,
2003) and chronic VNS reduces plasma levels of angiotensin II (Zhang et
al., 2009), another potent pro-ﬁbrotic mediator.
6.1. The direct and indirect effect of VNS on sympathetic signalling and a di-
rect effect on ventricular electrophysiology
Stimulating the cardiac vagus results in bradycardia and some stud-
ies have suggested that the anti-arrhythmic effect is attenuated if the
heart rate is controlled (Goldstein et al., 1973; Kent et al., 1973, 1974;
Myers et al., 1974; Zuanetti et al., 1987), although recent data (Brack
et al., 2011; Kalla et al., 2016) has demonstrated that an anti-ﬁbrillatory
property of cholinergic signalling persists independent of heart rate. Ni-
tric oxide (NO) plays a key role in mediating vagal bradycardia and its
mechanism is site-speciﬁc (Paton et al., 2002). Depolarisation of nerve
terminals leads to release of acetycholine (ACh) which binds to sino-
atrial node (SAN) cell muscarinic receptors (M2) coupled to inhibitory
G proteins (Schulz et al., 2005). This leads to hyperpolarisation via stim-
ulation of ACh-activated K+ channels, reduction in adenylate cyclase
(and therefore cAMP), with subsequent decrease in the
hyperpolarisation-activated current, If, and PKA dependent phosphory-
lation of the L-type calcium current, ICaL, thereby reducing diastolic
depolarisation and heart rate (Lakatta et al., 2010). Neuronal NOS
(nNOS) is thought to be the critical source of NO in modulating vagal
neurotransmission. This mechanism was suggested by the observation
that NO donors (Herring and Paterson, 2001) and inhibitors of NOS
and soluble guanylyl cyclase (sGC) (Herring et al., 2000) do not affect
the heart rate response to ACh in vitro. In addition, application of ACh
to atria from nNOS knockout mice also remains intact despite impaired
vagal responses (Choate et al., 2001). Release of radio-labelled ACh from
ﬁeld stimulated atria is also increased by NO donors and abolished by
sGC inhibitors (Herring and Paterson, 2001), further supporting a pre-
synaptic, autocrine role rather than direct co-transmitter function in
terms of vagal control of heart rate. Mechanistically, NO augments para-
sympathetic transmission by augmentingpre-synaptic cAMP-PKA regu-
lation of N- and P-type calcium channels by a cGMP-PDE3 mediated
increase in cAMP which phosphorylates N-type channels leading to an
increase in ACh release (Herring et al., 2002).Recent data has demonstrated that the anti-ﬁbrillatory effect of di-
rect VNS is independent of heart rate but still dependent on NO (Brack
et al., 2011). The potential for a direct effect of VNS on ventricular elec-
trophysiology has been studied in a series of experiments utilising a
Langendorff perfused rabbit heart with intact bilateral vagal innerva-
tion. Left or right VNS ﬂattened the action potential duration (APD) res-
titution curve and prolonged ventricular effective refractory period
(ERP) (Ng et al., 2001) in keeping with the anti-arrhythmic mechanism
suggested by the restitution hypothesis (Weiss et al., 2005). Amore de-
ﬁned anti-ﬁbrillatory effectwas also demonstrated by determining ven-
tricular ﬁbrillation threshold (VFT) to remove the confounding effect of
heart rate reduction. VFT was increased with left or right VNS despite
differential heart rate reductions seen from each limb (Ng et al.,
2007), and in contrast to the earlier studies of VNS, these observations
were seen in the absence of background sympathetic stimulation. This
would support a direct ventricular effect rather than dependence on in-
direct ‘accentuated antagonism’ of adrenergic signalling. The pattern of
ventricular repolarisation was also reversed with bilateral VNS (Ng et
al., 2007), although the mechanistic signiﬁcance of this remains uncer-
tain and requires further investigation.
The dogma of vagal or cholinergic signalling has been that release of
ACh from cholinergic nerve terminals results in activation ofM2 ACh re-
ceptors (AChR) and downstream coupling to Gi, eNOS and Gk signalling
cascades. Gi inhibits adenylyl cyclase and thereby reduces cAMP depen-
dent stimulation of L-type Ca2+ current (LTCC) and phosholamban. M2
dependent stimulation of eNOS activity has also been proposed as a
mechanism for accentuated antagonism of β-receptor stimulation
when cAMP levels are already elevated (Balligand et al., 1993; Han et
al., 1995). Generation of NO via this pathwaymay increase sGC genera-
tion of cGMP via stimulation of PDE2 (Han et al., 1998). The role of the
pathway is controversial (Herring et al., 2002) and many groups have
observed antagonism of heart rate and contractility to be intact despite
genetic deletion of eNOS (Martin et al., 2006). M2 receptor activation of
Gk increases IKACh andmanypropose that this is themainmechanismby
which cholinergic accentuated antagonism is mediated (Mesirca et al.,
2013).
In the innervated, rabbit heart preparation described above, the anti-
ﬁbrillatory effect of direct left or right VNSwas interestinglymaintained
in the presence of atropine, but abolished with non-speciﬁc NOS inhibi-
tion and restored with supplementation of L-arginine, the substrate for
NOS (Brack et al., 2007, 2011). This suggests a non-receptor dependent,
nitrergic anti-arrhythmic mechanism of VNS. The release of NO was
conﬁrmed with an increase in epicardial DAF-2 ﬂuorescence. The effect
of VNS on APD restitution was also lost with NOS inhibition, but the ef-
fect on ERP was maintained, suggesting divergent pathways mediating
these effects on ventricular electrophysiology. Central modulation of
rat vagal signalling via optogenetic silencing of preganglioninc neurons
from thedorsal ventralmotor nucleus (Mastitskaya et al., 2012) demon-
strates some beneﬁcial effects on electrophysiology. During central si-
lencing of DVMN with combined β-blockade and muscarinic blockade,
reductions in ventricular ERP and VT could be abolished by NOS block-
ade with 7-nitroinidazole (Machhada et al., 2015) suggestive of para-
crine NO signalling. Others however, observe contrasting results (Kalla
et al., 2016). Using an isolated rat heart preparation, stimulation with
anACh analogue, carbamylcholine (CCh) that is resistant to cholinester-
ase, results in an increase in VFT independent of heart rate. CCh perfu-
sion also resulted in prolongation of APD during ﬁxed rate pacing and
ﬂattening of the APD restitution curve that is consistentwith an anti-ar-
rhythmic effect. This rise in VFT was also dependent upon the genera-
tion of NO as the effect was abolished by non-selective and neuronal
NOS blockade and downstream blockade of sGC. CCh perfusion also in-
creased NO metabolites (NOx), and this was prevented by mecamyl-
amine, a speciﬁc inhibitor of the nicotinic AChR demonstrating that
the source of NO was neuronal.
Therefore, observations in the rat are in keeping with the observa-
tions in the rabbit that nNOS derived NO is a key component of the
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anti-ﬁbrillatory effect is abolished by atropine in keeping with the
established autocrine role of NO (Herring and Paterson, 2001). Further-
more, anNOdonor, can increase VFT, an effect abolished by atropine, in-
dicating that NO was acting upstream of the muscarinic receptor. The
most likely mechanistic explanation of these observations is the nNOS
derived NO from parasympathetic ganglia facilitates ACh release from
sites of ganglionic projections via a cGMP-PDE3 dependent pathway in-
creasing PKA dependent phosphorylation of N-type calcium channels
(Herring and Paterson, 2001), but thismay be dependent on the density
of innervation and the expression or activity of the nNOS enzyme.
Notwithstanding the above observations, these data must also be
consideredwithin the limitations of themodel systems studied. Sensory
ﬁbres make up to 70% of the cervical vagus (Berthoud and Neuhuber,
2000) and they will also be recruited with direct stimulation of the
transected nerve and may inﬂuence the generation of nNOS derived
NO. The relevance of afferent ﬁbre stimulation has been assessed in a
porcine model of VNS with and without nerve transection (Yamakawa
et al., 2015). Here VNS without decentralisation activates afferent ﬁbres
in the ipsilateral vagus nerve with accompanying reﬂex inhibition of
cardiac parasympathetic efferent electrophysiological and haemody-
namic effects. Furthermore, the species dependent variation in para-
sympathetic projections may also contribute to the relative
importance of the two proposed pathways. However, the critical role
of muscarinic receptors is supported by the CCh experiments and this
is in keeping with established literature (Corr and Gillis, 1974; Yoon et
al., 1977; Vanoli et al., 1991; De Ferrari et al., 1992; De Ferrari et al.,
1993) and recent studies of VNS in ischaemia-reperfusion
(Shinlapawittayatorn et al., 2014).
The anti-arrhythmic role of NO in mediating vagal protection is sup-
ported by studies across multiple domains, and future studies will need
to further delineate the sites of action and optimum strategies to exploit
this effect therapeutically. Speculatively, a nicotinic receptor based NO
mediatedmechanism that converges on themuscarinic receptor is con-
ceivably amenable to a more targeted approach with gene therapy or a
pharmacological treatment strategy. Percutaneous cardiac gene transfer
of nNOS increases vagal neurotransmission and bradycardia (Mohan et
al., 2002) and reducesmortality three days postmyocardial infarction in
the guinea pig (Dawson et al., 2008). Whether gene transfer of nNOS
into cardiac cholinergic ganglia provides a direct anti-ﬁbrillatory action
on the ventricle that could be used therapeutically remains to be
established, although gene transfer of nNOS into the pig cervical vagus
increases cardiac baroreﬂex sensitivity (Heaton et al., 2005).
7. Neuromodulation targeting the cervical vagus nerve
Targeting the cardiac vagus with device therapy for heart failure is a
recent example of a translational bench to bedside research. The ﬁrst in
man trial of vagus nerve stimulation (VNS) (De Ferrari et al., 2011) was
a small, proof of concept study that demonstrated an improvement in
symptoms in patients with advanced heart failure treated with VNS.
However, larger, clinical studies such as ANTHEM-HF (Premchand et
al., 2014) and NECTAR-HR (Zannad et al., 2015) have yielded disap-
pointing results in terms of echocardiographic and clinical end points.
A larger, randomised clinical trial, INOVATE-HF (Hauptman et al.,
2012) has also recently reported no impact on heart failure events or
mortality in patients with ejection fractions b40% and New York Heart
Association (NYHA) class III symptoms (Gold et al., 2016). It is worth
highlighting that these trials employed a variety of different stimulation
currents and frequencies, different stimulation timings (continuous v′ R
wave synchronised bursts) as well as different approaches (left verses
right) all of which can impact on the efﬁcacy of the treatment
(Kember et al., 2014; Ardell et al., 2015). Trials to date have focused
on cardiac imaging and heart failure symptoms, but of considerable
mechanistic interest may be the potential role for appropriate VNS in
suppressing ventricular arrhythmia.8. Neuromodulation directly targeting the cardiac sympathetic ner-
vous system
The potential of the vagus nerve as a therapeutic target in heart fail-
ure continues to be the subject of clinical trials, but challenges remain in
delivering effective device therapy. Historically, pharmacological ap-
proaches such as cholinesterase inhibition (Behling et al., 2003;
Santos-Almeida et al., 2015) have also been limited. Therefore the
sympatho-adrenal axis has been the principal target for established
pharmacotherapies such as β-blockers and ACE inhibitors, with both
achieving signiﬁcant reductions in morbidity and mortality (ISIS-1,
1986; CONSENSUS, 1987; Pfeffer et al., 1992; CIBIS-II, 1999). However,
sudden cardiac death (SCD) remains a signiﬁcant clinical problem and
sympathetic activation is a key contributor in patients with andwithout
structural heart disease. Recent observations have led to neuro-axial
therapies directly targeting the sympathetic nervous system in the set-
ting of VT due to structural heart disease and channelopathies (Shen
and Zipes, 2014). Patients can presentwith VT that is recurrent or inces-
sant, resulting in haemodynamic compromise, multiple ICD shocks and
high mortality (Verma et al., 2004). Conventional management strate-
gies include trials of anti-arrhythmic medications and catheter ablation
(Pedersen et al., 2014), but recurrence of arrhythmia is common (Tung
et al., 2015). Neuromodulation by directly targeting the sympathetic
nervous systemhas demonstrated efﬁcacy in animal and human studies
and the commonest strategies employed are thoracic epidural anaes-
thesia and cardiac sympathetic denervation by stellectomy (CSD)
(Mahajan et al., 2005; Ajijola et al., 2012a). In the largest case series to
date, 41 patients underwent left or bilateral stellectomy for refractory
ventricular arrhythmia and failed catheter ablation (Vaseghi et al.,
2014). The majority of patients were taking anti-arrhythmic drugs and
73% were taking β-blockers. CSD resulted in almost 50% of patients
being free of ICD shocks at 1 yearwith the remaining experiencing a sig-
niﬁcant reduction in arrhythmic events. A similar approach has been
used successfully in long QT syndrome (Moss and McDonald, 1971;
Schwartz et al., 1991) and catecholaminergic polymorphic VT (Collura
et al., 2009). In a series of 17 patients with LQTS or CPVT undergoing
left CSD for recurrent arrhythmia despite β-blockade in all, 87% of pa-
tients had a signiﬁcant reduction in arrhythmic events following LCSD.
In the setting of VT storm, thoracic epidural anaesthesia (Mahajan et
al., 2005)which acts tomodify sympathetic outﬂow rather than remove
neurotransmitter source, has also demonstrated efﬁcacy.
9. Indirect neuromodulation of cardiac sympatho-vagal balance
Other approaches to reducing cardiac sympathetic drive include
targeting higher centres via deep brain stimulation (DBS). DBS of the
periaqueductal grey is a treatment for chronic pain can also lead to in-
creases or decreases in blood pressure depending on the location of
the electrode (Green et al., 2005; Pereira et al., 2010)and alter heart
rate variability (Pereira et al., 2010) and baroreﬂex sensitivity by
inﬂuencing sympathetic outﬂow (Sverrisdottir et al., 2014). Spinal
cord stimulation at the level of T1–3 not only reduces cardiac sympa-
thetic drive but also targets neural processing via intrathoracic extra-
cardiac and intrinsic cardiac ganglia, as well as local circuit neurons
(Ardell et al., 2016). In early human trials, continuous spinal cord stim-
ulation improved symptoms and left ventricular dimensions in patients
with severe symptomatic heart failure (Tse et al., 2015) but not when
administered intermittently (Zipes et al., 2016). Afferent signalling can
also be targeted via denervating the carotid body (McBryde et al.,
2013; Schultz et al., 2015) or via renal sympathetic nerve ablation
(Esler, 2015) in order to reduce cardiac sympathetic drive. Renal dener-
vation can have beneﬁcial effects on cardiac electrophysiology in animal
models (Huang et al., 2014) and has been used to treat VT storm in pa-
tients (Remo et al., 2014), despite the disappointing results of the
Symplicity-HTN3 trial in drug resistant hypertension (Bhatt et al.,
2014).
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Although neuromodulation therapies offer promise in terms of
treatment of ventricular arrhythmias, it is interesting to note that
most to date have been trialed in patients already taking the maximally
tolerated doses of β-blockers (Herring, 2014). The mechanistic basis of
neuromodulation therapies may be found in emerging evidence of the
role of factors produced within the microenvironment of the heart, its
vasculature and between neuronal populations inﬂuencing local
sympatho-vagal balance. These neuromodulators may reside within
neurones (such as nNOS and NOS1-AP) or be mediators that are co-
transmitted with NE such as ATP, neuropeptide Y (NPY) and galanin,
or ACh such as vasoactive intestinal peptide (VIP). NPY and galanin
have been shown to be released with high-level sympathetic nerve
stimulation and reduce cholinergic ACh release and bradycardia
(Herring et al., 2008, 2012). In addition NPYmay act directly on ventric-
ular myocytes to trigger arrhythmias independent of beta-receptor
stimulation (Herring, 2015). Cardiac myocytes and the vasculature
also release a variety of mediators such as angiotensin II and natriuretic
peptides whichmay inﬂuence neuronal physiology in a paracrine man-
ner (Herring and Paterson, 2009), and these crosstalk and paracrine
pathways converge on neuronal and myocyte Ca2+ handling, thereby
potentially inﬂuencing arrhythmogenesis. Neuromodulation therapies
may not only remove the source of the principal neurotransmitter, but
also inﬂuence the local release of co-transmitters providing increased
efﬁcacy over conventional medical therapies. The functional signiﬁ-
cance of these pathways and potential therapeutics avenues in disease
states is yet to be established.
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